Isoliquiritigenin Inhibits Atherosclerosis by Blocking TRPC5 Channel Expression
Isoliquiritigenin (ISL) is a flavonoid isolated mainly from the licorice plant, a traditional Chinese herb. ISL has shown anticancer, anti-inflammatory, antioxidant, and antidiabetic activities. However, the pharmaceutical effects of ISL on atherosclerosis are seldom explored. In this study, we used...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Cardiovascular Therapeutics |
| Online Access: | http://dx.doi.org/10.1155/2020/1926249 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566307386556416 |
|---|---|
| author | Jie Qi Jianguo Cui Baobin Mi Xiaohong Yan Wenwen Xu Hui Ma Qingtan Zhang Fang Xu |
| author_facet | Jie Qi Jianguo Cui Baobin Mi Xiaohong Yan Wenwen Xu Hui Ma Qingtan Zhang Fang Xu |
| author_sort | Jie Qi |
| collection | DOAJ |
| description | Isoliquiritigenin (ISL) is a flavonoid isolated mainly from the licorice plant, a traditional Chinese herb. ISL has shown anticancer, anti-inflammatory, antioxidant, and antidiabetic activities. However, the pharmaceutical effects of ISL on atherosclerosis are seldom explored. In this study, we used apolipoprotein E (ApoE) knockout mouse model and angiotensin II- (Ang II-) stimulated vascular smooth muscle cells (VSMCs) to elucidate the pharmacological mechanism of ISL to inhibit atherosclerosis. We found that in ApoE−/− mice ISL could attenuate atherosclerotic lesion, reduce serum lipid levels, and inhibit TRPC5 expression. In vitro, ISL inhibited Ang II-stimulated proliferation of VSMCs and suppressed Ang II-induced TRPC5 and PCNA expressions in a dose-dependent fashion. In conclusion, our findings provide novel insight into the pharmacological effects of ISL on atherosclerosis and suggest that ISL is beneficial for cardiovascular protection. |
| format | Article |
| id | doaj-art-e476c43e5d384c198a53e3db6c9264b3 |
| institution | Kabale University |
| issn | 1755-5914 1755-5922 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiovascular Therapeutics |
| spelling | doaj-art-e476c43e5d384c198a53e3db6c9264b32025-02-03T01:04:39ZengWileyCardiovascular Therapeutics1755-59141755-59222020-01-01202010.1155/2020/19262491926249Isoliquiritigenin Inhibits Atherosclerosis by Blocking TRPC5 Channel ExpressionJie Qi0Jianguo Cui1Baobin Mi2Xiaohong Yan3Wenwen Xu4Hui Ma5Qingtan Zhang6Fang Xu7Department of Geriatrics, Binzhou Medical University Hospital, No. #661 Yellow River Road No. 2, Binzhou, Shandong 256603, ChinaDepartment of Geriatrics, Binzhou Medical University Hospital, No. #661 Yellow River Road No. 2, Binzhou, Shandong 256603, ChinaDepartment of Geriatrics, Binzhou Medical University Hospital, No. #661 Yellow River Road No. 2, Binzhou, Shandong 256603, ChinaDepartment of Geriatrics, Binzhou Medical University Hospital, No. #661 Yellow River Road No. 2, Binzhou, Shandong 256603, ChinaDepartment of Geriatrics, Binzhou Medical University Hospital, No. #661 Yellow River Road No. 2, Binzhou, Shandong 256603, ChinaDepartment of Geriatrics, Binzhou Medical University Hospital, No. #661 Yellow River Road No. 2, Binzhou, Shandong 256603, ChinaDepartment of Geriatrics, Binzhou Medical University Hospital, No. #661 Yellow River Road No. 2, Binzhou, Shandong 256603, ChinaDepartment of Pathophysiology, Binzhou Medical University, 346# Guanhai Road, Yantai, Shandong 264003, ChinaIsoliquiritigenin (ISL) is a flavonoid isolated mainly from the licorice plant, a traditional Chinese herb. ISL has shown anticancer, anti-inflammatory, antioxidant, and antidiabetic activities. However, the pharmaceutical effects of ISL on atherosclerosis are seldom explored. In this study, we used apolipoprotein E (ApoE) knockout mouse model and angiotensin II- (Ang II-) stimulated vascular smooth muscle cells (VSMCs) to elucidate the pharmacological mechanism of ISL to inhibit atherosclerosis. We found that in ApoE−/− mice ISL could attenuate atherosclerotic lesion, reduce serum lipid levels, and inhibit TRPC5 expression. In vitro, ISL inhibited Ang II-stimulated proliferation of VSMCs and suppressed Ang II-induced TRPC5 and PCNA expressions in a dose-dependent fashion. In conclusion, our findings provide novel insight into the pharmacological effects of ISL on atherosclerosis and suggest that ISL is beneficial for cardiovascular protection.http://dx.doi.org/10.1155/2020/1926249 |
| spellingShingle | Jie Qi Jianguo Cui Baobin Mi Xiaohong Yan Wenwen Xu Hui Ma Qingtan Zhang Fang Xu Isoliquiritigenin Inhibits Atherosclerosis by Blocking TRPC5 Channel Expression Cardiovascular Therapeutics |
| title | Isoliquiritigenin Inhibits Atherosclerosis by Blocking TRPC5 Channel Expression |
| title_full | Isoliquiritigenin Inhibits Atherosclerosis by Blocking TRPC5 Channel Expression |
| title_fullStr | Isoliquiritigenin Inhibits Atherosclerosis by Blocking TRPC5 Channel Expression |
| title_full_unstemmed | Isoliquiritigenin Inhibits Atherosclerosis by Blocking TRPC5 Channel Expression |
| title_short | Isoliquiritigenin Inhibits Atherosclerosis by Blocking TRPC5 Channel Expression |
| title_sort | isoliquiritigenin inhibits atherosclerosis by blocking trpc5 channel expression |
| url | http://dx.doi.org/10.1155/2020/1926249 |
| work_keys_str_mv | AT jieqi isoliquiritigenininhibitsatherosclerosisbyblockingtrpc5channelexpression AT jianguocui isoliquiritigenininhibitsatherosclerosisbyblockingtrpc5channelexpression AT baobinmi isoliquiritigenininhibitsatherosclerosisbyblockingtrpc5channelexpression AT xiaohongyan isoliquiritigenininhibitsatherosclerosisbyblockingtrpc5channelexpression AT wenwenxu isoliquiritigenininhibitsatherosclerosisbyblockingtrpc5channelexpression AT huima isoliquiritigenininhibitsatherosclerosisbyblockingtrpc5channelexpression AT qingtanzhang isoliquiritigenininhibitsatherosclerosisbyblockingtrpc5channelexpression AT fangxu isoliquiritigenininhibitsatherosclerosisbyblockingtrpc5channelexpression |